Compare · BIO vs BNGO
BIO vs BNGO
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Bionano Genomics Inc. (BNGO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and BNGO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $7.80B, about 580.7x BNGO ($13.4M).
- Over the past year, BIO is up 29.6% and BNGO is down 68.6% - BIO leads by 98.2 points.
- BNGO has hit the wire 8 times in the past 4 weeks while BIO has been quiet.
- BIO has more recent analyst coverage (12 ratings vs 5 for BNGO).
- Company
- Bio-Rad Laboratories Inc.
- Bionano Genomics Inc.
- Price
- $292.57+0.42%
- $1.16-1.28%
- Market cap
- $7.80B
- $13.4M
- 1M return
- +15.02%
- -13.11%
- 1Y return
- +29.55%
- -68.65%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2018
- News (4w)
- 0
- 8
- Recent ratings
- 12
- 5
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Bionano Genomics Inc.
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Latest BIO
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
Latest BNGO
- Bionano Genomics Inc. filed SEC Form 8-K: Leadership Update
- GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 24 shares, decreasing direct ownership by 9% to 239 units (SEC Form 4) (for withholding tax)
- CHIEF OPERATING OFFICER Oldakowski Mark covered exercise/tax liability with 27 shares, decreasing direct ownership by 3% to 868 units (SEC Form 4) to satisfy withholding tax
- CHIEF MEDICAL OFFICER Chaubey Alka covered exercise/tax liability with 24 shares, decreasing direct ownership by 4% to 620 units (SEC Form 4) (for withholding tax)
- Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 7 shares, decreasing direct ownership by 3% to 253 units (SEC Form 4) (withholding obligation)
- Bionano Genomics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
- Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
- SEC Form 4 filed by Director Rajkovic Aleksandar
- SEC Form 4 filed by Director Linney Yvonne